Maravai LifeSciences initiatives FY income close to mid-range steerage; shares fall

SAN DIEGO – Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI), identified for supplying reagents and companies to the life science analysis and biotechnology sectors, has indicated its anticipated complete income for the fiscal 12 months 2024.

Shares fell 5% in after-hours commerce Wednesday.

The corporate’s preliminary year-end outcomes, that are topic to plain year-end changes, counsel that its income is anticipated to align with the mid-point of its beforehand forecasted vary of $255 million to $265 million.

This projection is positioned within the neighborhood of the consensus estimate, which predicts a fiscal 12 months income of roughly $260.78 million.

This text was generated with the help of AI and reviewed by an editor. For extra info see our T&C.